bullish

Alkem Labs (BUY): Poor US sales and inventory provision affect Q4

157 Views28 May 2021 14:01
Syndicated
Alkem Labs reported a below-expected Q4FY21 with +7%/4% YoY sales/EBITDA growth.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 1-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
BOB Capital Markets Ltd.
External broker reports(aggregated public sources)
BOB Capital Markets Ltd
IndiaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x